<DOC>
	<DOCNO>NCT00814671</DOCNO>
	<brief_summary>The goal Phase 2 study determine microbiological activity safety rifapentine give component multidrug intensive phase treatment smear-positive pulmonary TB . Funding Source- FDA OOPD</brief_summary>
	<brief_title>Study Daily Rifapentine Pulmonary Tuberculosis</brief_title>
	<detailed_description>Prospective phase II , open-label , single center study experimental rifapentine regimen evaluate use two-stage design . Adults ( HIV-negative , HIV-positive CD4 &gt; 200 cells/cu mm ) suspect pulmonary tuberculosis meet eligibility criterion randomize receive one three intensive phase regimen . Intensive phase regimen consist daily isoniazid , pyrazinamide , ethambutol , plus one following : rifampin 600 mg daily OR rifapentine 450 mg daily OR rifapentine 600 mg daily . Randomization stratify presence/absence cavitation baseline chest radiograph . In Stage 1 , 15 subject randomize arm , follow enrollment pause efficacy safety assessment . Any rifapentine regimen fewer 6 11 evaluable participant week 8 culture conversion discard . Stage 2 randomize subject remain `` accepted arm '' maximum 36 additional subject per arm . All subject continue TB treatment conventional continuation phase treatment . Study Site Study subject recruit University Cape Town inpatient ward outpatient clinic . Estimated Study Duration It estimate 18 month require recruitment enrollment study subject . The estimated duration participation study subject 18 month , include 2 month experimental intensive phase TB treatment , 4 month non-experimental conventional continuation phase TB treatment , additional 12 month follow-up TB relapse . Study Management Study subject study visit day 0 , 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 sputum collection adverse event assessment . Safety laboratory monitoring perform day 14 , 28 , 42 , 56 consist complete blood count , serum alanine aminotransferase , serum total bilirubin , serum creatinine . Steady state pharmacokinetic analysis perform approximately day 28 . Subjects additional study visit week 10 month 4 , 6 , 12 , 18 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifapentine</mesh_term>
	<criteria>1 . Suspected pulmonary tuberculosis acidfast bacillus stain smear expectorate sputum . Patients extrapulmonary manifestation tuberculosis , addition smearpositive pulmonary disease , eligible enrollment . 2 . No prior history tuberculosis disease tuberculosis treatment 3 . No treatment fluoroquinolones 2 month precede initiation study drug . 4 . Age &gt; 18 year 5 . Weight ≥ 50 kg ≤ 80 kg 6 . Karnofsky score least 60 ( require occasional assistance able care his/her need ; see Appendix ) 7 . Signed informed consent 8 . Ability adhere study followup 9 . Women childbearing potential must agree practice adequate ( barrier ) method birth control abstain heterosexual intercourse study therapy . 10 . HIV negative , HIVpositive CD4 &gt; 200 cells/cu mm 11 . Laboratory parameter do , 14 day prior , screen ( result available review study personnel ) : Serum alanine aminotransferase ( ALT ) activity ≤ 2 time upper limit normal Serum total bilirubin level ≤ 2 time upper limit normal Serum creatinine level less equal upper limit normal Hemoglobin level least 7.0 g/dL Platelet count least 100,000/mm3 Negative pregnancy test ( woman childbearing potential ) 1 . Pregnant breastfeed 2 . Known intolerance allergy study drug 3 . Concomitant disorder condition isoniazid ( INH ) , rifamycins , pyrazinamide ( PZA ) , ethambutol ( EMB ) contraindicate . These include severe hepatic damage , acute liver disease cause , acute uncontrolled gouty arthritis . 4 . Current plan therapy , intensive phase TB therapy cyclosporine tacrolimus , HIV antiretroviral ( ARV ) therapy , unacceptable interaction rifamycins . 5 . Any medical psychosocial condition , , view study investigator , make study participation inadvisable . 6 . Pulmonary silicosis 7 . Central nervous system TB</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>